Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AltruBio Inc.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
California-based AbGenomics is looking for a new partner for its humanised monoclonal antibody against CD-162, AbGn-168H, which was in development for the treatment of psoriasis and other immunological diseases under a collaboration with Boehringer Ingelheim.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- AbGenomics International, Inc.
- AbGenomics Corporation
- AbGenomics Holding Ltd.
- AltruBio Taiwan, Inc.